Great news! This week, the U.S. Food and Drug Administration (FDA) approved the first generic versions of Zyprexa and Zyprexa Zydis for the treatment of schizophrenia and bipolar disorder. This isn’t just great news, it is incredible news! In 2010, Zyprexa was number 17 on the top 200 drugs in the U.S. market by sales, garnering almost three billion dollars in revenue, according to Pharmacy Times. The article went on to explain that generic drugs represented 78 percent of the total number of prescriptions dispensed in the United States last year.
According to a report, from the Centers for Disease Control and Prevention (CDC), on the burden of mental illness, bipolar disorder is the most expensive behavioral health care diagnosis, costing more than double what a diagnosis of depression costs an individual. The economic burden of schizophrenia is typically greatest during the first year after the initial episode.
In our current economic environment, patients and providers are constantly searching for the most effective treatment options, while at the same time acutely aware of cost and spending. Prescribers are forced to choose between which treatment options best meets the needs of a patient and which options a patient can afford, if they can afford treatment at all. Here’s what you need to know about generic drugs, a quick summary of the FDA news release about generic olanzapine and, of course, The Bottom Line.
What Do You Need to Know About Generic Drugs?
- Generic drugs approved by the FDA are therapeutically equivalent to the brand-name versions
- Generic drugs have the same high quality, strength, purity and stability as the brand-name drugs
- The manufacturing, packaging and testing sites for generic drugs must pass the same quality standards as the brand-name drugs
What Did the FDA Say?
- The approval of generic olanzapine offers greater access to a widely used treatment option
- The availability of affordable treatment options benefits patients with long-term conditions that must be carefully managed
- Olanzapine must be dispensed with a Medication Guide outlining the risks and adverse reactions patients should be aware of when taking olanzapine
- Olanzapine has a black boxed warning that the drug can increase the risk of death in elderly people who have psychosis resulting from confusion and memory loss
The Bottom Line
- Generic olanzapine was approved to treat schizophrenia and bipolar disorder
- Olanzapine is not approved for treating psychosis in elderly people who have dementia
- Serious reactions may include high blood sugar, increased cholesterol and triglycerides, and weight gain
- Generic olanzapine tablets will be manufactured by Dr. Reddy’s Laboratories Ltd. and Teva Pharmaceuticals USA
- Generic olanzapine orally disintegrating tablets will be manufactured by Apotex Inc., Dr. Reddy’s Laboratories Ltd., and Par Pharmaceuticals Inc.
